Patrick Ott

Patrick Ott is a leader in personalized cancer vaccine development at Dana-Farber Cancer Institute, having conducted the seminal clinical trial demonstrating that individualized neoantigen peptide vaccines can generate robust T cell responses and durable clinical benefit in melanoma patients. His work on the NeoVax personalized vaccine platform established the proof of concept that computationally predicted neoantigens can effectively prime anti-tumor immunity in humans. He continues to advance neoantigen vaccine approaches in combination with checkpoint inhibitors across multiple tumor types.